Phlow’s Post

In the wake of the significant attention GLP-1s like Wegovy are receiving across the U.S. and now Europe, it's an exciting time to reflect on the evolving landscape of weight loss solutions. The innovation behind these treatments, especially with their potential expansion into addressing cardiovascular issues, highlights a promising frontier in healthcare. However, it also opens up a dialogue about the holistic approach to wellness. How do we balance the breakthroughs in pharmaceuticals with the timeless principles of diet and exercise? Is there a way to integrate these advancements seamlessly into a broader wellness strategy that emphasizes sustainable health practices? The willingness of patients to invest in their health, even out-of-pocket, underscores a significant shift towards prioritizing wellness. Yet, this enthusiasm also brings to light questions of accessibility and equity. How can we ensure these life-changing treatments are within reach for everyone who needs them? I'm curious to hear your thoughts on how we can foster an inclusive environment in healthcare that values both innovation and traditional approaches to health and wellness. Let's discuss how we can support each other in navigating this exciting yet complex landscape. #Wegovy #GLP1s #weightloss #Ozempic #pharmaceuticals #marketaccess #healthyliving #sustainability #communitydiscussion" Read more here: https://lnkd.in/eCYWdFfz

Shared the platform on the subject of medicines supply and specifically supply shortages. A focus on price reductions (VPAG), global supply issues, medicine purchasing by large multiples having priority over community pharmacies, inequity in the provision of medicines (HRT discussion), actions of the EU and individual member states and how that could affect the UK. Lots of food for thought. #medicines #pharmacies #VPAG

The  American Conference Institute (“ACI”) will be hosting a series of go-to forums on critical topics including novel therapeutics, cosmetics/personal care products and Paragraph IV disputes. HP&M is proud to have our professionals participating in these important events. Read our blog post at link below for registration information (including discount codes) and to see where John Claud, Charles Raver and Kurt Karst will be speaking. https://lnkd.in/eB_PEdwJ #fda #drugdevelopment #regulatory #pharmaceuticals

Don't miss out – act fast! Elevate your expertise in Medical Device Regulation! Join our comprehensive course of Medical Device Regulation Masterclass - MENA providing insights into MENA region regulations, market dynamics, and technical documentation. Gain a solid foundation and unlock opportunities in the medical and pharmaceutical industry. Register now: https://bit.ly/3Osed8e Secure your spot and enjoy an exclusive early bird 15% discount! #MedicalDevice #PRAconsultancy #RegulatoryAffairs #MENA #Masterclass

It's not new news that GLP-1s have taken the U.S. by storm. But, European patients are showing a surprising willingness to pay out-of-pocket for new weight-loss products like Novo Nordisk's Wegovy (semaglutide). So much so that parent company Novo Holdings just bought Catalent for $16.5B to give the Danish drugmaker three more production sites, to help bolster its supply chain. With talks of "flexible" pricing and the possibility of extending use to cardiovascular issues, what does the future of market access look like for this in-demand class of products? #Wegovy #GLP1s #weightloss #Ozempic #pharmaceuticals #marketaccess Read more here: https://lnkd.in/eCYWdFfz

In Europe, patients opting to pay for weight loss drugs out of pocket reflects a commitment to investing in their health. Individuals. started prioritizing their well-being, viewing these expenses as worthwhile investments for achieving their weight loss goals and overall health improvement." #willingness #wellbeing #weightloss #pharma #europe #marketaccess

As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions to the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) that contain real-world evidence (RWE). Applications submitted to CBER containing RWE that meet reporting criteria have been published. Data will be added annually to represent submissions by fiscal year (FY) from FYs 2023 through 2027. #fda #cber #realworlddata #realworldevidence #observationalstudies https://lnkd.in/eUV4dDgP

And just like that, registration has come to a close for the 2024 Collaboration Conference. Starting on February 28th, we'll be joined visionary leaders across the industry, all coming together to fuel one goal: commercial success in the pharmaceutical and medical device industries. Let the countdown begin! #lifesciences #MedDevice #CollaborationConference #Pharma #SynergistixConference

Stay ahead in the rapidly evolving Biologics sector with our in-depth report on the most common FDA audit observations. Read the Ebook to understand more about Biologics FDA findings. #biotechnology #manufacturing #fda https://lnkd.in/gZk5rA9k

Take a second to learn more about Thomas Dubin, one of our CI board members and a pharmaceutical executive and attorney. 👏 Tom's knowledge and experience has made him a key player on our team since the fall of 2020. 💡 #CIBoardMemberSpotlight